Mammary tumors in dogs.

What it is

Mammary tumors arise from the milk-producing glandular tissue of the breast chain. Roughly half of canine mammary tumors are malignant; the rest are benign adenomas, fibroadenomas, or mixed tumors. The split between benign and malignant is roughly 50/50 — much higher malignant proportion than in humans — and you can't reliably tell which is which from a physical exam alone.

Most affected dogs are intact (unspayed) or were spayed late in life. Spaying before the first estrous cycle reduces lifetime mammary cancer risk dramatically; spaying before the second cycle reduces it less but still meaningfully; later spays provide little protective benefit.

Signs to watch for

• A firm or soft lump along the mammary chain (running down the underside from the chest to the inguinal region).
• Multiple lumps — mammary tumors often appear in groups or sequence.
• Ulceration, redness, or discharge from a mass — usually a sign of malignancy and/or inflammatory mammary carcinoma.
• Rapid growth in any previously stable lump.

How veterinarians diagnose it

Surgical removal with histopathology is the standard — FNA is often suggestive but cytology can't reliably grade or fully characterize mammary tumors. Excising the mass with appropriate margins solves both the diagnostic and therapeutic problem in one step.

Staging — three-view chest radiographs are essential as the lung is the most common metastatic site. Abdominal ultrasound is reasonable for larger tumors or any suspicion of regional spread.

Spay (if not already done) is often performed concurrently or shortly after, particularly for hormonally-receptive tumors.

What treatment usually looks like

• Surgical resection is the foundation. Approach varies from lumpectomy for small benign lesions to regional or unilateral chain mastectomy for malignant disease — the surgeon will recommend based on tumor size, location, and number.
• Concurrent or subsequent spay (ovariohysterectomy) for intact females — reduces risk of new tumors developing on the contralateral chain.
• Adjuvant chemotherapy (carboplatin, doxorubicin, or others) is considered for malignant tumors with high-grade or invasive features, or with evidence of vascular invasion.
• Inflammatory mammary carcinoma (IMC) is a separate aggressive subtype — diffusely red, painful, often non-surgical — typically managed with palliative care plus piroxicam.

Prognosis

Benign tumors removed with clean margins are typically cured. Malignant tumors vary by histologic grade, size, lymphovascular invasion, and lymph node status. Many dogs with small, well-differentiated, completely excised malignant mammary tumors have excellent outcomes — long-term survival is common.

Larger tumors, high-grade tumors, those with vascular invasion, or those that have spread regionally carry shorter median survivals. Inflammatory mammary carcinoma has the worst prognosis of the canine mammary cancers.

Questions to ask your vet

• What surgical approach makes sense — lumpectomy, regional, or chain mastectomy?
• Should we spay at the same time?
• Has the chest been imaged for metastasis?
• What did the histopathology show — type, grade, vascular invasion, margins?
• Do we need adjuvant chemotherapy based on the path report?
• Should we watch the contralateral chain closely?

Where to learn more

Veterinary teaching hospitals at most accredited US vet schools maintain owner-facing fact sheets on common cancers. Peer-reviewed journals — JAVMA, Veterinary and Comparative Oncology, Frontiers in Veterinary Science — are accessible through PubMed. The American College of Veterinary Internal Medicine (ACVIM) and the Veterinary Cancer Society publish consensus statements you can ask your vet to walk you through.

For clinical trials enrolling dogs with this diagnosis, see the SciRouter Vet trial finder — we index AVMA, NCI COTC, and twelve university registries.